Announcement • Jul 15
Starpharma Holdings Limited has filed a Follow-on Equity Offering in the amount of AUD 31.990561 million. Starpharma Holdings Limited has filed a Follow-on Equity Offering in the amount of AUD 31.990561 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 56,123,791
Price\Range: AUD 0.57
Discount Per Security: AUD 0.0342
Transaction Features: Rights Offering Breakeven Date Change • May 20
Forecast to breakeven in 2027 The analyst covering Starpharma Holdings expects the company to break even for the first time. New forecast suggests losses will reduce by 64% to 2026. The company is expected to make a profit of AU$100.0k in 2027. Average annual earnings growth of 92% is required to achieve expected profit on schedule. Announcement • Sep 18
Starpharma Holdings Limited, Annual General Meeting, Nov 14, 2025 Starpharma Holdings Limited, Annual General Meeting, Nov 14, 2025. Announcement • Oct 03
Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024 Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024. Reported Earnings • Aug 23
Full year 2024 earnings released: AU$0.02 loss per share (vs AU$0.038 loss in FY 2023) Full year 2024 results: AU$0.02 loss per share (improved from AU$0.038 loss in FY 2023). Revenue: AU$9.76m (up 132% from FY 2023). Net loss: AU$8.17m (loss narrowed 48% from FY 2023). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 04
First half 2024 earnings released: AU$0.003 loss per share (vs AU$0.02 loss in 1H 2023) First half 2024 results: AU$0.003 loss per share (improved from AU$0.02 loss in 1H 2023). Revenue: AU$8.03m (up 369% from 1H 2023). Net loss: AU$1.03m (loss narrowed 88% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings. Announcement • Oct 02
Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023 Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023, at 14:00 AUS Eastern Standard Time. Announcement • Sep 19
Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold Viruses This winter, in order to maximise defences against respiratory viruses, VIRALEZE nasal spray is available to provide a protective barrier against a broad spectrum of respiratory viruses. VIRALEZE has shown the ability to trap and block a wide range and multiple strains of respiratory and cold viruses. Key Features of VIRALEZE Barrier Nasal Spray: Barrier Formulation: VIRALEZE is specifically designed to target the nose where respiratory viruses first attach and multiply. It provides a protective physical barrier in the nose that is intended to trap and block respiratory and cold viruses before an infection develops, helping to reduce exposure to virus. Broad-Spectrum: VIRALEZE traps and blocks a wide range of respiratory viruses, including common cold and flu viruses. Its physical mechanism of action means it traps and blocks a broad spectrum of respiratory and cold viruses, including emerging viruses and strains. Scientifically Proven: Rigorous laboratory studies have demonstrated the ability of VIRALEZE to trap and block respiratory and cold viruses, and to reduce the incidence and severity of respiratory virus infection in stringent models. User-Friendly Application: VIRALEZE is easy to use and store at room temperature, making it easy to incorporate into daily routines. With a simple application, individuals can take proactive steps to safeguard their respiratory health. Useful in a variety of settings: The use of VIRALEZE fits seamlessly into various lifestyles, including work, travel and commuting, and leisure activities, such as attending sports and music events. Its non-invasive application ensures that VIRALEZE does not impact daily life. Starpharma is also currently completing a post-market study of VIRALEZE™ at St Peter's Hospital, UK, where its ability to reduce viral load in COVID-19-positive patients is being evaluated. Board Change • Sep 05
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Russell Basser was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Aug 28
Starpharma Holdings Limited Announces Change of Company Secretary Starpharma Holdings Limited announced, in accordance with ASX Listing Rule 3.16.1, that Tracy Weimar has resigned as Company Secretary, a role that was conducted for an interim period. Justin Cahill, Starpharma's Chief Financial Officer and Company Secretary, continues as the person responsible for communication with ASX under ASX Listing Rule 12.6. New Risk • Jun 23
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €91.1m (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.7% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Revenue is less than US$5m (AU$4.7m revenue, or US$3.2m). Market cap is less than US$100m (€91.1m market cap, or US$99.8m). New Risk • Jun 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.7% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Revenue is less than US$5m (AU$4.7m revenue, or US$3.2m). Announcement • Jun 09
Starpharma Announces Resignation of Jackie Fairley as Chief Executive Officer Starpharma announced that following her significant tenure as the Company's Chief Executive Officer, Dr. Jackie Fairley has advised the Board that she intends to retire during 2024. Jackie and the Board are keen to ensure an orderly transition and have agreed that she will continue in the role until a successor is ready to commence, providing leadership and continuity throughout the transition period. Reported Earnings • Feb 28
First half 2023 earnings released: AU$0.02 loss per share (vs AU$0.021 loss in 1H 2022) First half 2023 results: AU$0.02 loss per share (improved from AU$0.021 loss in 1H 2022). Revenue: AU$1.71m (down 16% from 1H 2022). Net loss: AU$8.28m (loss narrowed 2.0% from 1H 2022). Revenue is expected to decline by 30% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.5%. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings. Announcement • Feb 02
Starpharma Holdings Limited Announces Board Changes Starpharma Holdings Limited announced that Ms Tracy Weimar from Vistra Australia has been appointed as interim Company Secretary, effective 1 February 2023. Ms Weimar is a Fellow of the Governance Institute of Australia (FGIA) and a Graduate of the Australian Institute of Company Directors (GAICD), with over 20 years of commercial, company secretarial and non-executive director experience in the pharmaceutical/biotech industry in both the large and small cap sectors. Ms Weimar is currently a Company Secretary of, and provides company secretarial services to, various ASX listed, unlisted public and private companies, predominately in biotechnology. With Ms Weimar's appointment, Mr. Nigel Baade will step down as Company Secretary of the Company, effective 1 February 2023. Mr. Baade will continue in the role of Chief Financial Officer (CFO) until his departure in March 2023, as previously announced on 21 December 2022. Starpharma is well advanced in its search for a replacement CFO /Company Secretary and will update the market at the conclusion of this process. Announcement • Jan 31
Starpharma Holdings Limited Appoints Russell Basser as Non-Executive Director, Effective from 20 February 2023 The Board of Starpharma Holdings Limited announced the appointment of Dr. Russell Basser as an independent non-executive director, effective from 20 February 2023. Dr Basser is a medical oncologist and former corporate executive with over 30 years of international medical and biopharmaceutical experience, including 21 years at CSL. Dr. Basser has substantial expertise in international drug and vaccine development, having held multiple senior executive roles whilst at CSL, including Senior Vice President (SVP) of Research and Development at CSL Seqirus; Chief Medical Officer at CSL Limited /CSL Behring; and SVP of Global Clinical Research and Development at CSL Behring /CSL Limited. As SVP of Global Clinical Research and Development at CSL Behring, Dr Basser was responsible for globalising CSL's Clinical Research and Development group, and for conception and execution of CSL's clinical trial strategies across a broad range of therapeutic areas from Phase 1 through to commercialisation. Dr Basser was a founding member of CSL Seqirus' executive leadership team in 2015 as SVP of Research and Development until his retirement in April 2022. In this role, he was responsible for all R&D activities through to commercialisation, including new global registrations of CSL Seqirus' seasonal, pre-pandemic and pandemic influenza vaccines, major process improvements and annual influenza vaccine updates. He also had oversight of the establishment of the framework for real world effectiveness evaluation that led to enhanced understanding of the health benefits of differentiated influenza vaccines. Prior to joining CSL, Dr Basser was a practicing medical oncologist at the Royal Melbourne and Western Hospitals and had an appointment at the Ludwig Institute for Cancer Research. He also worked as an Experimental Medicine Physician for AstraZeneca in the UK and was the Director of the Centre for Developmental Cancer Therapeutics (now Cancer Trials Australia) for seven years. Reported Earnings • Aug 26
Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.05 loss in FY 2021) Full year 2022 results: AU$0.04 loss per share (up from AU$0.05 loss in FY 2021). Net loss: AU$16.2m (loss narrowed 18% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 8% per year. Reported Earnings • Feb 22
First half 2022 earnings: EPS in line with expectations, revenues disappoint First half 2022 results: AU$0.021 loss per share (up from AU$0.027 loss in 1H 2021). Net loss: AU$8.45m (loss narrowed 19% from 1H 2021). Revenue missed analyst estimates by 30%. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Recent Insider Transactions • Sep 02
Independent Non-Executive Director recently bought €44k worth of stock On the 27th of August, Lynda Cheng bought around 60k shares on-market at roughly €0.74 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €132k more in shares than they have sold in the last 12 months. Reported Earnings • Aug 26
Full year 2021 earnings released: AU$0.05 loss per share (vs AU$0.039 loss in FY 2020) Full year 2021 results: Net loss: AU$19.7m (loss widened 34% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Executive Departure • Aug 04
Independent Non-Executive Deputy Chairman Peter Turvey has left the company On the 29th of July, Peter Turvey's tenure as Independent Non-Executive Deputy Chairman ended after 9.4 years in the role. As of March 2021, Peter still personally held 193.16k shares (€81k worth at the time). A total of 2 executives have left over the last 12 months. Breakeven Date Change • Jun 12
Forecast to breakeven in 2022 The analyst covering Starpharma Holdings expects the company to break even for the first time. New forecast suggests the company will make a profit of AU$16.5m in 2022. Average annual earnings growth of 71% is required to achieve expected profit on schedule. Is New 90 Day High Low • Feb 04
New 90-day high: €1.00 The company is up 18% from its price of €0.85 on 06 November 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.96 per share. Is New 90 Day High Low • Dec 29
New 90-day high: €0.98 The company is up 4.0% from its price of €0.95 on 25 September 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.86 per share. Is New 90 Day High Low • Dec 08
New 90-day low: €0.76 The company is down 19% from its price of €0.94 on 09 September 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.58 per share. 
